Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 105 - 137
Опубликована: Янв. 1, 2025
Язык: Английский
Journal of Controlled Release, Год журнала: 2021, Номер 341, С. 844 - 868
Опубликована: Дек. 22, 2021
Язык: Английский
Процитировано
34
Scientific Reports, Год журнала: 2023, Номер 13(1)
Опубликована: Апрель 4, 2023
Abstract Dysregulation of microRNAs (miRNA) in small extracellular vesicles (sEV) such as exosomes have been implicated the pathogenesis amyotrophic lateral sclerosis (ALS). Although circulating cell-free miRNA extensively investigated ALS, sEV-derived miRNAs not systemically explored yet. Here, we performed RNA sequencing analysis serum sEV and identified 5 differentially expressed a discovery cohort 12 patients 11 age- sex-matched healthy controls (fold change > 2, p < 0.05). Two them (up- down-regulation miR-23c miR192-5p, respectively) were confirmed separate validation (18 15 controls) by droplet digital PCR. Bioinformatic revealed that these two interact with distinct sets target genes involve biological processes relevant to pathomechanism ALS. Our results suggest from ALS profiles which may be potentially useful biomarker disease.
Язык: Английский
Процитировано
15
Non-coding RNA Research, Год журнала: 2024, Номер 9(2), С. 523 - 535
Опубликована: Фев. 6, 2024
The discovery of disease-specific biomarkers, such as microRNAs (miRNAs), has the potential to transform landscape Amyotrophic Lateral Sclerosis (ALS) by facilitating timely diagnosis, monitoring treatment response, and accelerating drug discovery. This advancement will ultimately improve quality life survival rate ALS patients. Despite more than a decade research, no miRNA biomarker candidate been translated into clinical practice. We conducted systematic review meta-analysis quantitatively synthesize data from original studies that analyzed expression liquid biopsies via PCR compared them healthy controls. Our analysis encompasses 807 observations 31 studies, stratified according their source tissue. identified consistently dysregulated miRNAs in serum (hsa-miR-3665, -4530, -4745–5p, −206); blood (hsa-miR-338–3p, -183–5p); cerebrospinal fluid (hsa-miR-34a-3p); plasma (hsa-miR-206); neural-enriched extracellular vesicles (hsa-miR-146a-5p, −151a-5p, −10b-5p, −29b-3p, −4454). meta-analyses provided additional support for upregulation hsa-miR-206, hsa-miR-338–3p, hsa-miR-146a-5p hsa-miR-151a-5p, downregulation hsa-miR-183–5p, hsa-miR-10b-5p, hsa-miR-29b-3p, hsa-miR-4454 consistent indicators ALSacross independent studies. findings provide valuable insights current understanding miRNAs' patients on researchers' choices methodology. work contributes ongoing efforts towards discovering biomarkers.
Язык: Английский
Процитировано
5
Brain Communications, Год журнала: 2024, Номер 6(5)
Опубликована: Янв. 1, 2024
Blood-based diagnostic biomarkers for amyotrophic lateral sclerosis will improve patient outcomes and positively impact novel drug development. Critical to the development of such is robust method validation, optimization replication with adequate sample sizes neurological disease comparative blood samples. We sought test an biomarker derived from diverse samples determine if it specific. Extracellular vesicles were extracted plasma obtained individuals diagnosed sclerosis, primary Parkinson's healthy controls. Immunoaffinity purification was used create a neural-enriched extracellular vesicle fraction. MicroRNAs measured across cohorts using real-time polymerase chain reaction. A Kruskal-Wallis assess differences in microRNAs followed by
Язык: Английский
Процитировано
5
Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 105 - 137
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0